Michael hofman
Michael Hofman/X

Michael Hofman: New Frontiers in PSMA Radioligand Therapy

Michael Hofman, Director of Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC) at Peter MacCallum Cancer Centre, shared a post on X:

“New Frontiers in PSMA Radioligand Therapy
Is this the ‘hottest’ session at ASCO25 ??
  • VIOLET: First-in-human trial of Terbium-161
  •  BULLSEYE: Lu-PSMA in oligo-metastatic disease
  •  ENZA-p: BiomarkersMichael Hofman

More posts featuring ASCO25.